Sanofi's Dupixent sales grow 45 percent in Q1
The sales for eczema drug Dupixent from Sanofi are growing steadily. During the year's first quarter, sales have increased by more than 45 percent.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Sales for Sanofi's major blockbuster drug Dupixent are mainly fueled by its use as a treatment for atopical dermatitis, but the drug's other approved indications are also gaining ground.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi's diabetes business shrinks again
For subscribers
Sanofi hits bullseye in phase III trial of treatment for RSV
For subscribers
.jpg&w=384&q=75)
